APRIL CAR-T cells

APRIL CAR-T cells are a type of chimeric antigen receptor (CAR) T cell therapy engineered to target multiple myeloma by recognizing two antigens—B-cell maturation antigen (BCMA) and transmembrane activator and CAML interactor (TACI)—on malignant plasma cells. The targeting domain of these CARs is based on the natural ligand "A proliferation inducing ligand" (APRIL), which binds both BCMA and TACI with high affinity. This dual targeting approach aims to increase tumor-binding sites and reduce the risk of disease escape due to loss or downregulation of a single antigen. Preclinical studies have shown that trimeric forms of the APRIL binding moiety enhance polyfunctionality and immune synapse formation compared to monomeric forms. Early clinical trials in relapsed/refractory multiple myeloma have demonstrated antitumor activity with manageable side effects, though long-term efficacy remains under investigation[1][2][3][4][5].

Other names

autologous BCMA/TACI-targeted trimeric APRIL-based CAR T cellsAPRIL-based chimeric antigen receptor T cells